Mitochondrial targeting of [alpha]-tocopheryl succinate enhances its pro-apoptotic efficacy: A new paradigm for effective cancer therapy

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61388963%3A_____%2F11%3A00360075" target="_blank" >RIV/61388963:_____/11:00360075 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/86652036:_____/11:00360075 RIV/68378050:_____/11:00360075 RIV/00027162:_____/11:#0000797

Výsledek na webu

<a href="http://dx.doi.org/10.1016/j.freeradbiomed.2011.02.032" target="_blank" >http://dx.doi.org/10.1016/j.freeradbiomed.2011.02.032</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.freeradbiomed.2011.02.032" target="_blank" >10.1016/j.freeradbiomed.2011.02.032</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Mitochondrial targeting of [alpha]-tocopheryl succinate enhances its pro-apoptotic efficacy: A new paradigm for effective cancer therapy

Popis výsledku v původním jazyce

Mitochondria are emerging as intriguing targets for anti-cancer agents.We tested here a novel approach,whereby the mitochondrially targeted delivery of anti-cancer drugs is enhanced by the addition of a triphenylphosphonium group (TPP+). A mitochondrially targeted analog of vitamin E succinate (MitoVES),modified by tagging the parental compound with TPP+,induced considerably more robust apoptosis in cancer cells with a 1?2 log gain in anti-cancer activity compared to the unmodified counterpart, while maintaining selectivity for malignant cells.This is because MitoVES associates with mitochondria and causes fast generation of ROS that then trigger mitochondria-dependent apoptosis, involving transcriptional modulation of the Bcl-2 family proteins.MitoVESproved superior in suppression of experimental tumors compared to the untargeted analog. We propose that mitochondrially targeted delivery of anti-cancer agents offers a new paradigm for increasing the efficacy of anti-cancer compounds

Název v anglickém jazyce

Mitochondrial targeting of [alpha]-tocopheryl succinate enhances its pro-apoptotic efficacy: A new paradigm for effective cancer therapy

Popis výsledku anglicky

Mitochondria are emerging as intriguing targets for anti-cancer agents.We tested here a novel approach,whereby the mitochondrially targeted delivery of anti-cancer drugs is enhanced by the addition of a triphenylphosphonium group (TPP+). A mitochondrially targeted analog of vitamin E succinate (MitoVES),modified by tagging the parental compound with TPP+,induced considerably more robust apoptosis in cancer cells with a 1?2 log gain in anti-cancer activity compared to the unmodified counterpart, while maintaining selectivity for malignant cells.This is because MitoVES associates with mitochondria and causes fast generation of ROS that then trigger mitochondria-dependent apoptosis, involving transcriptional modulation of the Bcl-2 family proteins.MitoVESproved superior in suppression of experimental tumors compared to the untargeted analog. We propose that mitochondrially targeted delivery of anti-cancer agents offers a new paradigm for increasing the efficacy of anti-cancer compounds

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

EB - Genetika a molekulární biologie

OECD FORD obor

—

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>Z - Vyzkumny zamer (s odkazem do CEZ)

Rok uplatnění

2011

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Free Radical Biology and Medicine

ISSN

0891-5849

e-ISSN

—

Svazek periodika

50

Číslo periodika v rámci svazku

11

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

10

Strana od-do

1546-1555

Kód UT WoS článku

000290603700010

EID výsledku v databázi Scopus

—